Entero Therapeutics, Inc.
ENTONASDAQHealthcare
$2.85
$-0.15(-5.00%)
Market Cap$13582331
P/E Ratio—
52W High$5.84
52W Low$0.969
Entero Therapeutics, Inc. (ENTO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ENTO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.04M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.03M | $0.11M | $0.54M |
| Gross Profit | $0.00M | $0.00M | ($0.03M) | ($0.11M) | ($0.54M) |
| Gross Margin %(computed) | 0.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.93M | $0.00M | $5.03M | $0.69M | $38.32M |
| G&A Expenses | $5.50M | $0.01M | $10.74M | $11.99M | $18.38M |
| Total Operating Expenses | $6.43M | $0.02M | $15.77M | $12.68M | $56.70M |
| Operating Income | ($7.08M) | ($0.02M) | ($15.77M) | ($12.68M) | ($59.06M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.01M | $0.00M |
| Interest Expense | ($0.49M) | $0.00M | $0.02M | $0.02M | $0.01M |
| Income Before Tax | ($6.55M) | ($0.02M) | ($15.79M) | ($14.63M) | ($58.54M) |
| Income Tax Expense | $0.00M | ($0.00M) | $0.00M | $0.00M | $0.00M |
| Net Income | ($6.55M) | ($18.06M) | ($15.79M) | ($14.63M) | ($58.54M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.16 | $-3.88 | $-46.96 | $-407.37 | $-27544.98 |
| Wtd Avg Shares | 1.62M | 4.65M | 0.34M | 0.04M | 0.00M |
| EBITDA | ($7.08M) | $0.03M | ($15.74M) | ($14.58M) | ($57.99M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Entero Therapeutics, Inc. data
About Entero Therapeutics, Inc. (ENTO) Income Statement
Entero Therapeutics, Inc. (ENTO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ENTO reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.01B) — a net profit margin of -18078.34%.
Frequently asked questions
ENTO · 4 questionsEntero Therapeutics, Inc. (ENTO) reported revenue of $0.00B for 2025, up —% year-over-year.
ENTO revenueENTO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08